CL2017003228A1 - Fragmentos mutantes de proteína ras - Google Patents

Fragmentos mutantes de proteína ras

Info

Publication number
CL2017003228A1
CL2017003228A1 CL2017003228A CL2017003228A CL2017003228A1 CL 2017003228 A1 CL2017003228 A1 CL 2017003228A1 CL 2017003228 A CL2017003228 A CL 2017003228A CL 2017003228 A CL2017003228 A CL 2017003228A CL 2017003228 A1 CL2017003228 A1 CL 2017003228A1
Authority
CL
Chile
Prior art keywords
ras protein
protein mutant
muting
region
mutant fragments
Prior art date
Application number
CL2017003228A
Other languages
English (en)
Inventor
Jon Amund Eriksen
Original Assignee
Targovax Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP15172418 priority Critical
Application filed by Targovax Asa filed Critical Targovax Asa
Publication of CL2017003228A1 publication Critical patent/CL2017003228A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • A61K39/001164GTPases, e.g. Ras, Rho
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y306/00Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

<p>SE DESCRIBE UN PÉPTIDO ADECUADO PARA PRODUCIR UNA RESPUESTA INMUNE. EL PÉPTIDO CORRESPONDE A UN FRAGMENTO DE LA PROTEÍNA RAS Y COMPRENDE UNA REGIÓN DE 8 AMINOÁCIDOS LA CUAL INCLUYE UNA POSICIÓN MUTANTE DE LA PROTEÍNA RAS. LA REGIÓN TIENE AL MENOS 6 RESIDUOS DE AMINOÁCIDOS, DIFERENTES A LOS DE LA POSICIÓN MUTANTE, LOS CUALES SON IDÉNTICOS A LOS DE LA REGIÓN CORRESPONDIENTE DE LA PROTEÍNA RAS. EL PÉPTIDO TIENE UNA MUTACIÓN PUNTUAL EN EL AMINOÁCIDO QUE CORRESPONDE A LA POSICIÓN MUTANTE Y LA POSICIÓN MUTANTE ES LA POSICIÓN 146 O 117 DE LA PROTEÍNA RAS.</p>
CL2017003228A 2015-06-16 2017-12-15 Fragmentos mutantes de proteína ras CL2017003228A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP15172418 2015-06-16

Publications (1)

Publication Number Publication Date
CL2017003228A1 true CL2017003228A1 (es) 2018-07-13

Family

ID=53404437

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003228A CL2017003228A1 (es) 2015-06-16 2017-12-15 Fragmentos mutantes de proteína ras

Country Status (14)

Country Link
US (1) US20190374628A1 (es)
EP (1) EP3310808A1 (es)
JP (1) JP2018518177A (es)
KR (1) KR20180021072A (es)
CN (1) CN107922472A (es)
AU (1) AU2016280770A1 (es)
BR (1) BR112017025728A2 (es)
CA (1) CA2989373A1 (es)
CL (1) CL2017003228A1 (es)
HK (1) HK1248714A1 (es)
IL (1) IL256077D0 (es)
MX (1) MX2017015927A (es)
RU (1) RU2018101225A (es)
WO (1) WO2016202937A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018214556A1 (en) * 2017-02-01 2019-08-15 Modernatx, Inc. Immunomodulatory therapeutic mRNA compositions encoding activating oncogene mutation peptides
US20210213120A1 (en) * 2017-02-03 2021-07-15 The Medical College Of Wisconsin , Inc. Kras peptide vaccine compositions and method of use
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
CN110172480B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 双抗原表位融合基因重组慢病毒载体、抗原提呈细胞和ctl细胞及其构建方法和应用
CN110205298B (zh) * 2019-06-11 2020-05-15 焦顺昌 一种靶向kras突变的异体抗原递呈细胞、构建方法及肠癌特异性ctl细胞的制备方法
CN110184238A (zh) * 2019-06-11 2019-08-30 北京鼎成肽源生物技术有限公司 一种靶向kras多发突变肿瘤的特异性ctl细胞的制备方法及应用
WO2021087840A1 (zh) * 2019-11-07 2021-05-14 武汉华大吉诺因生物科技有限公司 肿瘤免疫治疗多肽及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
MX2008012392A (es) * 2006-03-27 2008-12-17 Globeimmune Inc Mutacion de ras, y composiciones y metodos relacionados con la misma.

Also Published As

Publication number Publication date
BR112017025728A2 (pt) 2018-08-07
CN107922472A (zh) 2018-04-17
WO2016202937A1 (en) 2016-12-22
IL256077D0 (en) 2018-01-31
KR20180021072A (ko) 2018-02-28
CA2989373A1 (en) 2016-12-22
RU2018101225A (ru) 2019-07-16
US20190374628A1 (en) 2019-12-12
HK1248714A1 (zh) 2018-10-19
JP2018518177A (ja) 2018-07-12
EP3310808A1 (en) 2018-04-25
MX2017015927A (es) 2018-04-18
AU2016280770A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
CL2017003228A1 (es) Fragmentos mutantes de proteína ras
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
PE20181046A1 (es) Anticuerpos anti-tigit y metodos de uso
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
CY1120729T1 (el) Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων
EA201890355A1 (ru) Новые способы индукции иммунного ответа
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
EA202090090A1 (ru) Включение неприродных нуклеотидов и способы с ними
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
BR112017008962A2 (pt) proteínas de fusão inibidoras de c1 esterase e usos das mesmas
MX2017012284A (es) Nuevos metodos para la seleccion de epitopos.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
WO2015187992A3 (en) Map44 polypeptides and constructs based on natural antibodies and uses thereof
AR107290A1 (es) ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
WO2015198240A3 (en) Compositions and methods for long acting proteins
BR112017006969A2 (pt) peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
AR104271A1 (es) Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante
CO2017012675A2 (es) Péptidos lipidados resistentes a proteasas
CO2017013404A2 (es) Variantes de il-37
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
MX2018000023A (es) Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina.
PH12017550079A1 (en) Composition for improving memory, learning ability and cognition